Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C3H5O3.Ag.H2O |
| Molecular Weight | 214.9535 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.[Ag+].CC(O)C([O-])=O
InChI
InChIKey=RKVLDPOOWODDMR-UHFFFAOYSA-M
InChI=1S/C3H6O3.Ag.H2O/c1-2(4)3(5)6;;/h2,4H,1H3,(H,5,6);;1H2/q;+1;/p-1
DescriptionSources: https://www.purebio.com/assets/001/5202.pdfhttp://google.com/patents/CN102923966Bhttps://www.ncbi.nlm.nih.gov/pubmed/19278981https://www.ncbi.nlm.nih.gov/pubmed/26897901https://www.ncbi.nlm.nih.gov/pubmed/25781988The legal airborne permissible exposure limit (PEL) is 11 mg/m^2 averaged over an 8-hour workshift.https://www.ncbi.nlm.nih.gov/pubmed/20429870https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+2930 | https://www.ncbi.nlm.nih.gov/pubmed/11294738Curator's Comment: description was created based on several sources, including
https://www.drugs.com/monograph/silver-nitrate.html |
https://www.ncbi.nlm.nih.gov/pubmed/18245232
Sources: https://www.purebio.com/assets/001/5202.pdfhttp://google.com/patents/CN102923966Bhttps://www.ncbi.nlm.nih.gov/pubmed/19278981https://www.ncbi.nlm.nih.gov/pubmed/26897901https://www.ncbi.nlm.nih.gov/pubmed/25781988The legal airborne permissible exposure limit (PEL) is 11 mg/m^2 averaged over an 8-hour workshift.https://www.ncbi.nlm.nih.gov/pubmed/20429870https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+2930 | https://www.ncbi.nlm.nih.gov/pubmed/11294738
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/monograph/silver-nitrate.html |
https://www.ncbi.nlm.nih.gov/pubmed/18245232
Silver iodide is an inorganic compound with the formula AgI. It is used as a photosensitive agent in photography, as a local antiseptic, as a chemical intermediate, and in cloud seeding for rain-making. The major hazards encountered in the use and handling of silver iodide stem from its toxicologic properties. Effects from exposure may include skin rashes, conjunctivitis, argyria (a permanent ashen-gray discoloration of skin, conjunctiva, and internal organs), headache, fever, hypersensitivity, laryngitis, and bronchitis.
Originator
Sources: Vestsi Akademii Navuk BSSR, Seryya Khimichnykh Navuk, Issue 2, Pages 69-73, Journal, 1990https://www.ncbi.nlm.nih.gov/pubmed/20429870
Curator's Comment: The medical uses of silver date back to at least the time of Hippocrates
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0071292 |
|||
Target ID: GO:0034505 |
|||
Target ID: GO:0071292 |
|||
Target ID: GO:0034505 |
|||
Target ID: GO:0071292 |
|||
Target ID: GO:0071292 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Advantage Arrest Silver Diamine Fluoride Approved UseUnknown |
|||
| Primary | Advantage Arrest Silver Diamine Fluoride Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Curative | Unknown Approved UseUnknown |
|||
| Curative | Unknown Approved UseUnknown |
|||
| Primary | Colloidal silver iodide Approved UseSolution containing 5 to 49% of colloidal silver iodide have been employed in the treatment of infections of the mucous membranes. Ointments, usually containing 5%, have been used in inflammatory conditions of the eye, ear, and nose. |
|||
| Primary | Colloidal silver iodide Approved UseSolution containing 5 to 49% of colloidal silver iodide have been employed in the treatment of infections of the mucous membranes. Ointments, usually containing 5%, have been used in inflammatory conditions of the eye, ear, and nose. |
|||
| Palliative | Unknown Approved UseAntiseptic Wound Cauterization |
|||
| Primary | Unknown Approved UseProphylaxis of gonococcal ophthalmia neonatorum. AAP recommends use of topical silver nitrate, povidone-iodine, or possibly erythromycin for prophylaxis of nongonococcal nonchlamydial conjunctivitis in neonates, ideally administered shortly after birth. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Lack of genotoxicity of silver iodide in the SCE assay in vitro, in vivo, and in the Ames/microsome test. | 1998 |
|
| A chemically intelligent antimicrobial coating for urologic devices. | 2000 Feb |
|
| New disinfection and sterilization methods. | 2001 Mar-Apr |
|
| Comparative efficacy of hand hygiene agents in the reduction of bacteria and viruses. | 2005 Mar |
|
| Photocatalytic degradation of pathogenic bacteria with AgI/TiO2 under visible light irradiation. | 2007 Apr 24 |
|
| Antibacterial activity and mechanism of action of the silver ion in Staphylococcus aureus and Escherichia coli. | 2008 Apr |
|
| Topical antimicrobials for burn wound infections. | 2010 Jun |
|
| Development of silica-coated silver iodide nanoparticles and their biodistribution. | 2012 Dec |
|
| Cleaning and decontamination efficacy of wiping cloths and silver dihydrogen citrate on food contact surfaces. | 2012 Jul |
|
| A novel silver iodide metalo-drug: experimental and computational modelling assessment of its interaction with intracellular DNA, lipoxygenase and glutathione. | 2014 Apr 22 |
|
| UCSF Protocol for Caries Arrest Using Silver Diamine Fluoride: Rationale, Indications and Consent. | 2016 Jan |
|
| An alternate technique of care using silver fluoride followed by stannous fluoride in the management of root caries in aged care. | 2016 Mar-Apr |
|
| Directional growth of Ag nanorod from polymeric silver cyanide: A potential substrate for concentration dependent SERS signal enhancement leading to melamine detection. | 2017 Aug 5 |
|
| The antifungal effects and mechanical properties of silver bromide/cationic polymer nano-composite-modified Poly-methyl methacrylate-based dental resin. | 2017 May 8 |
Sample Use Guides
Topical as a 1:80 dilution (30 ppm ionic silver).
Route of Administration:
Topical
10 mkl volume of undiluted human norovirus 20% faecal suspension was mixed with 90 mkl of SDC (Silver Dihydrogen Citrate) for various contact times (15, 30, 60, 120, 300, 600 and 1800 s). At each sampling time point, 20 mkl of this solution was added to 180 mkl of 10% solution of Dey/Engley (D/E) neutralizing broth (Thermo Fisher Scientific, Waltham, MA). Samples were aliquoted and frozen at -80°C prior to nucleic acid extraction.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
19025-99-1
Created by
admin on Sat Dec 16 10:08:38 GMT 2023 , Edited by admin on Sat Dec 16 10:08:38 GMT 2023
|
PRIMARY | |||
|
22600159
Created by
admin on Sat Dec 16 10:08:38 GMT 2023 , Edited by admin on Sat Dec 16 10:08:38 GMT 2023
|
PRIMARY | |||
|
67E6H10EYR
Created by
admin on Sat Dec 16 10:08:38 GMT 2023 , Edited by admin on Sat Dec 16 10:08:38 GMT 2023
|
PRIMARY | |||
|
m9926
Created by
admin on Sat Dec 16 10:08:38 GMT 2023 , Edited by admin on Sat Dec 16 10:08:38 GMT 2023
|
PRIMARY | Merck Index |
SUBSTANCE RECORD
